Abstract
The setup of tumorigenesis processes is generally associated with various events leading to abnormal expression of oncogenes and/or tumor suppressor genes. Recently, the expression and/or activity of a range of molecules involved in these processes were reported to require proteolytic processing of their precursor proteins by the serine proprotein convertases (PCs) in order to mediate their biological functions. These include adhesion molecules, proteases, growth factors, cytokines and their receptors. Since their discovery, the identification of new PCs substrates and specific PCs inhibitors became an attractive strategy in cancer therapy. In this review, we will report the implication of these enzymes and the processing of their substrates in tumor progression and metastasis. Newly reported studies on the potential use of the PCs as new therapeutic targets will be also discussed.
Keywords: Proprotein Convertases, furin, PACE4, PC5, PC7, cancer, metastasis, inhibitors, prosegments
Recent Patents on Anti-Cancer Drug Discovery
Title: The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Volume: 4 Issue: 1
Author(s): Rachid Lahlil, Fabien Calvo and Abdel-Majid Khatib
Affiliation:
Keywords: Proprotein Convertases, furin, PACE4, PC5, PC7, cancer, metastasis, inhibitors, prosegments
Abstract: The setup of tumorigenesis processes is generally associated with various events leading to abnormal expression of oncogenes and/or tumor suppressor genes. Recently, the expression and/or activity of a range of molecules involved in these processes were reported to require proteolytic processing of their precursor proteins by the serine proprotein convertases (PCs) in order to mediate their biological functions. These include adhesion molecules, proteases, growth factors, cytokines and their receptors. Since their discovery, the identification of new PCs substrates and specific PCs inhibitors became an attractive strategy in cancer therapy. In this review, we will report the implication of these enzymes and the processing of their substrates in tumor progression and metastasis. Newly reported studies on the potential use of the PCs as new therapeutic targets will be also discussed.
Export Options
About this article
Cite this article as:
Lahlil Rachid, Calvo Fabien and Khatib Abdel-Majid, The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002470
DOI https://dx.doi.org/10.2174/157489209787002470 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry Editorial [Hot Topic: Mechanisms of Drug Sensitivity and Resistance in Cancer (Guest Editor: Lorraine ODriscoll)]
Current Cancer Drug Targets Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Recent Advances in Metal-Organic Frameworks as Anticancer Drug Delivery Systems: A Review
Anti-Cancer Agents in Medicinal Chemistry Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells
Current Radiopharmaceuticals Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability
Medicinal Chemistry Bioactives in Disease Prevention and Health Promotion: Exploiting Combinatorial Effects
Current Bioactive Compounds Electrochemical Cell-based Biosensors for Biomedical Applications
Current Topics in Medicinal Chemistry Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates
Current Pharmaceutical Design The Radiosensitizing Effect of Olanzapine as an Antipsychotic Medication on Glioblastoma Cell
Current Radiopharmaceuticals Chondroitin Sulphate Decorated Polymeric Nanoparticles: An Effective Carrier for Enhancement of Lung Cancer Targeting Capabilities of Anticancer Drug
Current Nanomedicine Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry